# Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine

> **NIH NIH N01** · ACCESS TO ADVANCED HEALTH INSTITUTE · 2024 · $1,260,556

## Abstract

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases, including emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.

## Key facts

- **NIH application ID:** 11060583
- **Project number:** 272201800025C-P00013-9999-1
- **Recipient organization:** ACCESS TO ADVANCED HEALTH INSTITUTE
- **Principal Investigator:** CHRISTOPHER FOX
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,260,556
- **Award type:** —
- **Project period:** 2018-09-21 → 2025-11-22

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11060583

## Citation

> US National Institutes of Health, RePORTER application 11060583, Advanced Development and Clinical Evaluation of an Entamoeba Histolytica Vaccine (272201800025C-P00013-9999-1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/11060583. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*